Ticker: VKTX | Published: 2026-09-22
VKTX soars on obesity data
Viking Therapeutics is violently higher after reporting positive topline results from its obesity drug maintenance study showing durable weight loss, while obesity drug rivals like Eli Lilly and Novo slip on the competitive threat.
Sources: https://www.reuters.com/business/healthcare-pharmaceuticals/viking-therapeutics-obesity-drug-shows-22-weight-loss-stud